Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 8, 2020, Pages

  Denison, Hayley J ^a   Worswick, Julia ^b   Bond, Christine M ^c   Grimshaw, Jeremy M ^b   Mayhew, Alain ^d   Gnani Ramadoss, Shakila ^e   Robertson, Clare ^e   Schaafsma, Mary Ellen ^f   Watson, Margaret C ^g  

^a MASSEY UNIVERSITY   (New Zealand)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d BRUYÈRE RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f United Way of the Lower Mainland   (Canada)

^g UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUTOCONAZOLE; CLOTRIMAZOLE; ECONAZOLE; FENTICONAZOLE; FLUCONAZOLE; IMIDAZOLE; ITRACONAZOLE; MICONAZOLE; SERTACONAZOLE; TERCONAZOLE; TRIAZOLE; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

ANTIFUNGAL THERAPY; ARTICLE; CANDIDA ALBICANS; COMPARATIVE STUDY; DIARRHEA; DISEASE DURATION; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FUNGUS CULTURE; FUNGUS GROWTH; HUMAN; MICROSCOPY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA CANDIDIASIS; VAGINAL BURNING SENSATION; ACUTE DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; INTRAVAGINAL DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL BIAS;

ACUTE DISEASE; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; AZOLES; BIAS; CANDIDIASIS, VULVOVAGINAL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85089921167     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002845.pub3     Document Type: Article

References (66)

1. TM) Combination pack versus fluconazole: a clinical evaluation of time to symptomatic relief of vaginal yeast infections. Personal Products Company, Division of McNeil-PPC, Inc. CLINICAL STUDY REPORT DOCUMENT NO. CA-R-2411. x-wiley/crsRef/14363841
2. Williams NS, Phillips N, Bachmann G. Oral compared with local antifungal treatment of yeast infection: Comparison of time to symptomatic relief. In: Obstetrics and Gynecology. Conference: 63rd Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists San Francisco, CA United States. Conference Start 2015;125:2015. x-wiley/crsRef/14363842
3. Adetoro OO. Comparative trial of a single dose of fluconazole (150mg) and a single intravaginal tablet of clotrimazole (500mg) in the treatment of vaginal candidiasis. Current Therapeutic Research 1990;48(2):275-81. x-wiley/crsRef/2666594
4. Andersen GM, Barrat J, Bergan T, Brammer KW, Cohen J, Dcllenbach P, et al. A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis. British Journal of Obstetrics and Gynaecology 1989;96:226-32. x-wiley/crsRef/14363844
5. Brammer KW, Lees LJ. Single dose oral fluconazole in the treatment of vulvovaginal candidiasis: an interim analysis of a comparative study versus three-day intravaginal clotrimazole tablets. In: Fromtling RA, editors(s). Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Vol. n/a. South Africa: University of Michigan, 1987:151-6. x-wiley/crsRef/14363845
6. Lassus A. A comparative study of fluconazole and clotrimazole. Royal Society of Medicine Services International Congress and Symposium Series No. 160 1989;not specified:37-9. x-wiley/crsRef/14363846
7. Boag FC, Houang ET, Westrom R, McCormack SM, Lawrence AG. Comparison of vaginal flora after treatment with a clotrimazole 500 mg vaginal pessary or a fluconazole 150 mg capsule for vaginal candidosis. Genitourinary Medicine 1991;67:232-4. x-wiley/crsRef/2666600
8. Coric M, Barisic D, Lovric H. Fluconazole versus 3-day clotrimazole in the treatment of sporadic and recurrent vulvovaginal candidiasis. International Journal of Gynecology and Obstetrics 2006;95:171-2. x-wiley/crsRef/2666602
9. Goode MA, Karig AW, Carson DS, Hamadeh G. Single dose fluconazole versus clotrimazole in the treatment of vaginal candidiasis. In: International Pharmaceutical Abstracts (ASHP Midyear Clinical Meeting 27:SPG-61. December 1992. x-wiley/crsRef/2666604
10. Mendling W, Krauss C, Fladung B. A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses. Mycoses 2004;47:136-42. x-wiley/crsRef/14363848
11. Mikamo H, Izumi K, Ito K, Tamaya T. Comparative study of the effectiveness of oral fluconazole and intravaginal clotrimazole in the treatment of vaginal candidiasis. Infectious Diseases in Obstetrics and Gynaecology 1995;3:7-11. x-wiley/crsRef/14363850
12. Murina F, Grazziottin A, Felice R, Di Francesco S, Mantegazza V. Short course treatment of acute vulvovaginal candidiasis: comparative study between fluconazole and intra-vaginal fenticonazole [Il trattamento “short course” della candidosivulvovaginale acuta: studio comparativotra il fluconazolo ed il fenticonazolo intravaginale]. Minerva Medica 2011;63:1-2. x-wiley/crsRef/2666614
13. O-Prasertsawat P, Bourlert A. Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis. Sexually Transmitted Diseases 1995;22(4):228-30. x-wiley/crsRef/2666616
14. Osser S, Haglund A, Westrom L. Treatment of candidal vaginitis. A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole. Acta Obstetricia Gynaecologie Scandinavia 1991;70:73-8. x-wiley/crsRef/2666618
15. Westrom L, Haglund A, Svensson L. Fluconazole versus econazole in treating vaginal candidiasis. International Journal of Gynaecology and Obstetrics 1992;37(Supplement):29-31. x-wiley/crsRef/2666619
16. Roongpisuthipong A, Chalermchockcharoenkita A, Sirimaia K, Wanitpongpana P, Jaishuena A, Foongladdab S, et al. Safety and efficacy of a new imidazole fungicide, Sertaconazole, in the treatment of fungal vulvo-vaginitis:a comparative study using Fluconazole and Clotrimazole. Asian Biomedicine 2010;4(3):443-8. x-wiley/crsRef/14363852
17. Sanam M. Comparison of the efficacy of Clotrimazole and Itraconazole in the treatment of acute vulvovaginal candidiasis. Journal of the Bahrain Medical Society 2009;21(3):294-7. x-wiley/crsRef/2666625
18. Seidman LS, Skokos CK. An evaluation of butoconazole nitrate 2% Site Release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis. Infectious Diseases in Obstetrics and Gynecology 2005;13(4):197-206. x-wiley/crsRef/2666627
19. Sekhavat L, Tabatabaii A, Tezerjani FZ. Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. Journal of Infection and Public Health 2011;4:195-9. x-wiley/crsRef/2666629
20. Škerk V, Jakšić J, Žarković T, Škalko D, Begovac J. Postmarketing research of the efficacy and tolerability of fluconazole and clotrimazole in the treatment of vulvovaginal Candidiasis [Postmarketinško ispitivanje djelotvornosti i podnošljivosti liječenja vulvovaginalne kandidoze flukonazolom i klotrimazolom]. Croatian Journal of Infection 2006;26(3):135-7. x-wiley/crsRef/2666631
21. Slavin MB, Benrubi GI, Parker R, Griffin CR, Magee MJ. Single dose oral fluconazole vs intravaginal terconazole in treatment of candida vaginitis. Journal of Florida Medical Association 1992;79(10):693-6. x-wiley/crsRef/2666633
22. Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Bradley B, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. American Journal of Obstetrics and Gynaecology 1995;172:1263-8. x-wiley/crsRef/2666635
23. Stein GE, Christensen S, Mummaw N. Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis. DICP: the Annals of Pharmacotherapy 1991;25:582-5. x-wiley/crsRef/2666637
24. Stein GE, Mummaw N. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrobial Agents and Chemotherapy 1993;37(1):89-92. x-wiley/crsRef/2666639
25. Timonen H, Fluconazole Study Group. Shorter treatment for vaginal candidosis: comparison between single-dose oral fluconazole and three-day treatment with local miconazole. Mycoses 1992;35:317-20. x-wiley/crsRef/14363854
26. Timonen H, Hartikainen-Vahtera P, Kivijarvi A, Kohtamaki K, Kosunen M, Lehtonen L, et al. A double-blind comparison of the effectiveness of itraconazole oral capsules with econazole vaginal capsules in the treatment of vaginal candidosis. Drug Investigation 1992;4(6):515-520. x-wiley/crsRef/14363856
27. Tobin JM, Loo P, Granger SE. Treatment of vaginal candidosis: a comparative study of the efficacy and acceptability of itraconazole and clotrimazole. Genitourinary Medicine 1992;68:36-8. x-wiley/crsRef/2666645
28. Van Heusden AM, Merkus HM, Corbeij RS, Oosterbaan HP, Stoot JE, Ubachs HM, et al. Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis. Acta Obstetricia Gynaecologie Scandinavia 1990;69:417-22. x-wiley/crsRef/2666647
29. Van Heusden AM, Merkus HM, Euser R, Verhoeff A. A randomized, comparative study of a single oral dose of fluconazole versus a single topical dose of clotrimazole in the treatment of vaginal candidosis among general practitioners and gynaecologists. European Journal of Obstetrics and Gynaecology and Reproductive Biology 1994;55:123-7. x-wiley/crsRef/2666649
30. Woolley PD. Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis. British Journal of Clinical Practice 1995;49(2):65-6. x-wiley/crsRef/14363858
31. EUCTR2005-001360-31-IT. A multicenter, randomised, double- blind, between-patient, dose finding study to assess the safety, tolerability and efficacy of three different dosages (500, 1000 and 2000 mcg/g) of ABIO 12/01 gel, in comparison to an open active treatment, after a five-day vaginal administration to females with a confirmed clinical diagnosis of vulvovaginal candidiasis. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001360-31. x-wiley/crsRef/14363860
32. Fan S, Liu X, Liang Y. Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. Gynecologic and Obstetric Investigation 2015;80(2):113-8. x-wiley/crsRef/14363862
33. Fong IW. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vagianl candidiasis. Genitourinary Medicine 1992;68:374-7. x-wiley/crsRef/14363864
34. Herzog RE, Ansmann EB. Treatment of vaginal candidosis with fluconazole. Mycoses 1989;32(4):204-8. x-wiley/crsRef/14363866
35. Li T, Zhu Y, Fan S, Liu X, Liang. A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versusoral fluconazole for treating severe vulvovaginal candidiasis. Medical mycology 2015, June;53(5):455-61. x-wiley/crsRef/14363868
36. Lopez Olmos J, Parra, I. Vaginal candidiasis treatment: Prospective comparative study of three commercial products with a single dose. Clinica e Investigacion en Ginecologia y Obstetricia 1994;21(7):300-6. x-wiley/crsRef/14363870 [AN 94291310]
37. Mikamo H, Kawazoe K, Sato Y, Hayasaki Y, Tamaya T. Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis. Chemotherapy 1998;34:364-8. x-wiley/crsRef/2666661
38. Wermeling DP, McCraney SA. Single dose oral fluconazole versus miconazole vaginal cream in the treatment of vaginal candidiasis. International Pharmaceutical Abstracts (ASHP Midyear Clinical Meeting 27:SPG-61 (Dec) 1992) 1992;n/s:196. x-wiley/crsRef/14363872
39. Zhou X, Li T, Fan S, Zhu Y, Liu X, Guo X et al. The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. Mycoses 2016;59(7):419-282016. x-wiley/crsRef/14363874
40. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). National guideline for the management of vulvovaginal candidiasis. Sexually Transmitted Infections 1999;75(Supplement 1):S19-S20.
41. Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
42. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-9.
43. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
44. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical Microbiology Reviews 1999;12(4):501–17. [PMID: 10515900]
45. Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Critical Reviews in Microbiology 2016;42:905-27.
46. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al, GRADE Working Group. An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
47. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
48. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.
49. Brayfield A. Martindale: The complete drug reference. Thirty-ninth edition. London: Pharmaceutical Press, 2017.
50. Matheson A, Mazza D. Recurrent vulvovaginal candidiasis: a review of guideline recommendations. Australian and New Zealand Journal of Obstetrics and Gynaecology 2017;57(2):139-45.
51. Moher D, Fortin P, Jada AR, Juni P, Klassen T, Le Lorier J, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 1996;347:363-6.
52. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends in Microbiology 2003;11(6):272-9. [DOI: 10.1016/s0966-842x(03)00117-3]
53. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of Candidiasis. Clinical Infectious Diseases 2004;38(2):161-89.
54. Qin F, Wang Q, Zhang C, Fang C, Zhang L, Chen H, et al. Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. Infection and Drug Resistance 2018;11:1893–901.
55. Reed RD. Risk factors for Candida Vulvovaginitis. Obstetrical and Gynecological Survey 1992;47(8):551-60.
56. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Clinical Infectious Diseases 2000;30:662-78.
57. Rochon PA, Gurwitz JH, Simms RW. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine 1994;154:157-63.
58. Schulz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456-8.
59. Sobel JD. Candidal vulvovaginitis. Clinical Obstetrics and Gynaecology 1993;36(1):153-65.
60. Sobel JD. Vulvovaginal candidosis. Lancet 2007;369(9577):1961-71.
61. Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G. Prevalence and risk factors for fungal vaginitis caused by non-albicans species. American Journal of Obstetrics and Gynaecology 1997;176(1):138-41.
62. van Schalkwyk J, Yudin MH. Vulvovaginite: Dépistage et prise en charge de la trichomonase, de la candidose vulvovaginale et de la vaginose bactérienne. Journal of Obstetrics and Gynaecology Canada 2016;38(12):S587-S596.
63. Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No: CD000225. [DOI: 10.1002/14651858.CD000225]
64. Nurbhai M, Grimshaw J, Watson M, Bond CM, Mollison JA, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews 2007, Issue Issue 4. Art. No: CD002845. [DOI: 10.1002/14651858.CD002845.pub2]
65. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus local anti-fungal treatment of acute uncomplicated vulvovaginal candidiasis. Cochrane Database of Systematic Reviews 2000, Issue Issue 4. Art. No: CD002845. [DOI: 10.1002/14651858.CD002845]
66. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews 2001, Issue Issue 3. Art. No: CD002845. [DOI: 10.1002/14651858.CD002845]